AFX-200 series (Aphoenix)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameAFX-200 series (Aphoenix)
Drug Alias Namecytokine inhibitors (Aphoenix)AFX-200 series (Aphoenix)AFX-201AFX-245
ClassificationSmall molecules
Mechanisms of ActionCytokine receptors antagonistsTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsCytokine receptorsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAphoenix Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAphoenix Inc
Active IndicationsN/A
Inactive IndicationsPsoriasisArthritis, RheumatoidOsteoporosis

Other Information

ATC CodeN/A
Related LinksN/A